261 related articles for article (PubMed ID: 34180967)
1. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
[TBL] [Abstract][Full Text] [Related]
2. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
3. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
4. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease.
Schneider I; Allner C; Mühl L; Melde M; Lissner D; Mantzivi E; Glauben R; Vitali F; Becker E; Atreya I; Müller TM; Atreya R; Siegmund B; Neurath MF; Zundler S
Transl Res; 2023 Mar; 253():8-15. PubMed ID: 36272713
[TBL] [Abstract][Full Text] [Related]
7. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
Front Immunol; 2018; 9():1700. PubMed ID: 30131801
[TBL] [Abstract][Full Text] [Related]
8. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
9. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
10. Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
Ungar B; Malickova K; Hanžel J; Abu Arisha M; Paul S; Rocha C; Ben Shatach Z; Abitbol CM; Haj Natour O; Selinger L; Yavzori M; Fudim E; Picard O; Shoval I; Eliakim R; Kopylov U; Magro F; Roblin X; Chowers Y; Drobne D; Lukas M; Ben Horin S
J Crohns Colitis; 2021 Oct; 15(10):1707-1719. PubMed ID: 33837762
[TBL] [Abstract][Full Text] [Related]
11. Residual homing of α4β7-expressing β1
Becker E; Dedden M; Gall C; Wiendl M; Ekici AB; Schulz-Kuhnt A; Schweda A; Voskens C; Hegazy A; Vitali F; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
Gut; 2022 Aug; 71(8):1551-1566. PubMed ID: 34462337
[TBL] [Abstract][Full Text] [Related]
12. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
13. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
[TBL] [Abstract][Full Text] [Related]
15. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
[TBL] [Abstract][Full Text] [Related]
17. A product review of vedolizumab in inflammatory bowel disease.
Battat R; Dulai PS; Jairath V; Vande Casteele N
Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
[TBL] [Abstract][Full Text] [Related]
18. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy.
Akhtar HJ; Nguyen TM; Ma C; Jairath V
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e614-e623. PubMed ID: 33618025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
